Sage Journals: Discover world-class research

Abstract

Spanish

BACKGROUND

Evidence suggests that fibromyalgia is related to both chronic sympathetic hyperactivity and decreased levels of serotonin.

OBJECTIVE

To examine the efficacy of pindolol, a mixed serotonin (5-HT)_1A presynaptic autoreceptor/β-adrenergic receptor antagonist, in the treatment of fibromyalgia.

METHODS

An open trial was conducted using 20 female patients who met the American College of Rheumatology criteria for fibromyalgia. Treatment was initiated with pindolol 7.5 mg/day and titrated to a maximum dose of 15 mg/day for a total of 90 days. Primary outcome measures were tender point analysis and the Fibromyalgia Impact Questionnaire (FIQ). Anxiety and depression were measured with the Hamilton Depression and Anxiety Scales and Beck Depression Inventory.

RESULTS

There was significant improvement in primary outcome measures, including Tender Point Count (mean ± SD, 16.3 ± 2.2 vs 12.3 ± 5.0; F = 8.9; p < 0.001), Tender Point Score (24.4 ± 5.7 vs 17.5 ± 9.4; F = 7.8; p < 0.001), and FIQ (45.3 ± 10.8 vs 35.0 ± 15.0; F = 5.6; p < 0.005). The depression and anxiety scores did not change significantly among women who completed the study, while the impact on cardiovascular parameters was clinically insignificant.

CONCLUSIONS

While the current results are encouraging, further studies are needed to determine whether pindolol might be effective in the treatment of fibromyalgia. Limitations of this study include small group size and lack of placebo control.

Keywords

fibromyalgia pindolol

Get full access to this article

View all access options for this article.

References

1. Wolfe

, Smythe

, Yunus

, Bennett

, Bombardier

, Goldenberg

, The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.

2. Wolfe

, Ross

, Anderson

, Russell

, Hebert

. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.

3. Staud

. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002; 4: 299–305.

4. Martinez-Lavin

, Hermosillo

. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000; 29: 197–9.

5. Cohen

, Neumann

, Shore

, Amir

, Cassuto

, Buskila

. Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability. Semin Arthritis Rheum 2000; 29: 217–27.

6. Russell

, Michalek

, Vipraio

, Fletcher

, Javors

, Bowden

. Platelet ³H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–9.

7. Wolfe

, Cathey

, Hawley

. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23: 255–9.

8. Norregaard

, Volkmann

, Danneskiold-Samsoe

. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61: 445–9.

9. Goldenberg

, Mayskiy

, Mossey

, Ruthazer

, Schmid

. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852–9.

10.

10. Golightly

. Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 1982; 2: 134–47.

11.

11. Castro

, Harrison

, Pazos

, Sharp

. Affinity of (+/–)-pindolol, (–)-penbutolol, and (–)-tertatolol for pre- and postsynaptic serotonin 5-HT(_1A) receptors in human and rat brain. J Neurochem 2000; 75: 755–62.

12.

12. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.

13.

13. Sheehan

, Lecrubier

, Sheehan

, Amorim

, Janavs

, Weiller

, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 22–33.

14.

14. Blier

, Bergeron

. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15: 217–22.

15.

15. Burckhardt

, Clark

, Bennett

. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728–33.

16.

16. Clauw

. Fibromyalgia: more than just a musculoskeletal disease. Am Fam Physician 1995; 52: 843–51, 853–4.

17.

17. Hamilton

. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.

18.

18. Hamilton

. The assessment of anxiety disorders by rating. Br J Med Psychol 1959; 32: 50–65.

19.

19. Beck

, Waed

, Mendelson

. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71.

20.

20. Yunus

. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846–50.

21.

21. Sorensen

, Graven-Nielsen

, Henriksson

, Bengtsson

, Arendt-Nielsen

. Hyperexcitability in fibromyalgia. J Rheumatol 1998; 25: 152–5.

22.

22. Woolf

, Thompson

. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293–9.

23.

23. Stanton

, Mody

, Heinemann

. A role for N-methyl-d-aspartate receptors in norepinephrine-induced long-lasting potentiation in the dentate gyrus. Exp Brain Res 1989; 77: 517–30.

24.

24. Sarvey

, Burgard

, Decker

. Long-term potentiation: studies in the hippocampal slice. J Neurosci Methods 1989; 28: 109–24.

25.

25. McKenna

, Melzack

. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp Neurol 2001; 172: 92–9.

26.

26. Wood

. Fibromyalgia syndrome: a central role for the hippocampus—a theoretical construct. J Musculoskeletal Pain 2004; 12: 19–26.

27.

27. Miller

, Kubes

. Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 2002; 36: 707–12. DOI 10.1345/aph.1A184

28.

28. Rabiner

, Bhagwagar

, Gunn

, Sargent

, Bench

, Cowen

, Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 2001; 158: 2080–2.

29.

29. Smith

. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol 1998; 12: 407–13.

30.

30. Man in t Veld

, Schalekamp

. Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension: therapeutic implications. Br Med J (Clin Res Ed) 1981; 282: 929–31.

31.

31. Linde

, Rossnagel

. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225.

Open Trial of Pindolol in the Treatment of Fibromyalgia